| (Values in U.S. Thousands) | Jun, 2026 | Mar, 2026 | Dec, 2025 | Sep, 2025 | Jun, 2025 |
| Sales | 343,000 | 317,000 | 357,000 | 314,000 | 302,000 |
| Sales Growth | +8.20% | -11.20% | +13.69% | +3.97% | +13.53% |
| Net Income | 122,000 | 89,000 | 103,000 | 42,000 | 18,000 |
| Net Income Growth | +37.08% | -13.59% | +145.24% | +133.33% | -61.70% |
Indivior Pharmaceuticals Inc (INDV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Indivior Pharmaceuticals Inc., together with its subsidiaries, develops, manufactures and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders principally in the United States, Europe, Canada, Australia and internationally. Indivior Pharmaceuticals Inc., formerly known as Indivior PLC., is based in Chesterfield, Virginia.
Fiscal Year End Date: 12/31